These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 33081995)

  • 1. Predictors of good visual outcomes in patients with neovascular age-related macular degeneration in daily practice.
    Prieto-Del-Cura M; Villafruela-Güemes I; Recio-Gamo E; Sastre-Ibañez M; Fuentes-Ferrer ME
    J Fr Ophtalmol; 2020 Dec; 43(10):989-995. PubMed ID: 33081995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial).
    Menon G; Chandran M; Sivaprasad S; Chavan R; Narendran N; Yang Y
    Eye (Lond); 2013 Aug; 27(8):959-63. PubMed ID: 23743535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SEVERE VISUAL LOSS DURING ANTI-VEGF INTRAVITREAL INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: TIMING, PROGNOSIS, AND OPTICAL COHERENCE TOMOGRAPHY FINDINGS.
    Grassi MO; Monteleone G; Pozharitskiy N; Molfetta T; Boscia G; Alessio G; Boscia F
    Retina; 2023 Jul; 43(7):1081-1087. PubMed ID: 36913628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Retinal Thickness Variability and Visual Acuity Outcome during Maintenance Therapy Using Intravitreal Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration.
    Lai TYY; Lai RYK
    J Pers Med; 2021 Oct; 11(10):. PubMed ID: 34683165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of stoppage and recurrence of choroidal neovascularization with a Treat- Extend-Stop protocol: 4-year follow-up.
    Garay-Aramburu G; Rodriguez-Feijoo D; Aldazabal-Echeveste M; Del Barrio Z; Eiras-Fernández A; Piñero DP; Larrauri-Arana A
    J Fr Ophtalmol; 2023 Dec; 46(10):1204-1211. PubMed ID: 37658033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
    Quah NQX; Javed KMAA; Arbi L; Hanumunthadu D
    Clin Ophthalmol; 2024; 18():1479-1490. PubMed ID: 38827773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen.
    Hujanen P; Ruha H; Lehtonen E; Pirinen I; Huhtala H; Vaajanen A; Syvänen U; Tuulonen A; Uusitalo-Järvinen H
    BMJ Open Ophthalmol; 2023 Aug; 8(1):. PubMed ID: 37586826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial intelligence-based predictions in neovascular age-related macular degeneration.
    Ferrara D; Newton EM; Lee AY
    Curr Opin Ophthalmol; 2021 Sep; 32(5):389-396. PubMed ID: 34265783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.
    Khanani AM; Aziz AA; Khan H; Gupta A; Mojumder O; Saulebayeva A; Abbey AM; Almeida DRP; Avery RL; Banda HK; Barakat MR; Bhandari R; Chang EY; Haug SJ; London NJS; Mein L; Sheth VS; Wolfe JD; Singer MA; Danzig CJ
    Eye (Lond); 2023 Dec; 37(17):3574-3581. PubMed ID: 37173428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa Positively Affects Neovascular Age-Related Macular Degeneration.
    Figueroa AG; Boyd BM; Christensen CA; Javid CG; McKay BS; Fagan TC; Snyder RW
    Am J Med; 2021 Jan; 134(1):122-128.e3. PubMed ID: 32628915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Regimens of Neovascular Form of Age-Related Macular Degeneration. A Review.
    Fellner Z; Majtánová N; Kolář P; Krišková P; Kéri P
    Cesk Slov Oftalmol; 2024; 80(Ahead of print):1-7. PubMed ID: 38925899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of Neovascular Age-Related Macular Degeneration Disease Activity Criteria Use to Shorten, Maintain or Extend Treatment Intervals with Anti-VEGF in Clinical Trials: Implications for Clinical Practice.
    Patel PJ; Villavicencio P; Hanumunthadu D
    Ophthalmol Ther; 2023 Oct; 12(5):2323-2346. PubMed ID: 37477856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy.
    Gao Y; Teo YCK; Beuerman RW; Wong TY; Zhou L; Cheung CMG
    Sci Rep; 2020 Jan; 10(1):1341. PubMed ID: 31992792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global experience of faricimab in clinical settings - a review.
    Sharma A; Kumar N; Parachuri N; Loewenstein A; Bandello F; Kuppermann BD
    Expert Opin Biol Ther; 2024 Apr; 24(4):263-268. PubMed ID: 38551188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-8 Promoter Polymorphism -251 A/T and Treatment Response in Neovascular Age-related Macular Degeneration.
    Thomsen AK; Krogh Nielsen M; Liisborg C; Sørensen TL
    Clin Ophthalmol; 2024; 18():537-543. PubMed ID: 38405106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability of self-measurement of visual acuity in AMD patients with two electronic devices based on the ETDRS chart: A randomized study.
    Queguiner F; Bezirganyan K; Courjaret JC; Curel L; Penaranda G; Bonomini J; Righini Chossegros M
    J Fr Ophtalmol; 2024 Jan; 47(1):103911. PubMed ID: 37648551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: from clinical trials to real-world practice.
    Kim JH
    Expert Opin Drug Saf; 2024 Jun; 23(6):659-661. PubMed ID: 38696228
    [No Abstract]   [Full Text] [Related]  

  • 18. [Quality of life survey of 3,738 patients treated with intravitreal injections for age-related macular degeneration].
    Uzzan J; Haddad M; Salamé N
    J Fr Ophtalmol; 2024 Mar; 47(3):104075. PubMed ID: 38368762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Exudative Neovascular AMD a Chronic Disease? Analysis of Long-term Progression under Anti-VEGF Therapy.
    Gunnemann ML; Ziegler M; Book M; Gunnemann F; Rothaus K; Spital G; Gutfleisch M; Lange C; Lommatzsch AP; Pauleikhoff D
    Klin Monbl Augenheilkd; 2024 Jul; ():. PubMed ID: 38181813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response-a scoping review.
    Dervenis N; Dervenis P; Agorogiannis E
    BMJ Open Ophthalmol; 2024 Feb; 9(1):. PubMed ID: 38341189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.